Smith & Nephew's Supartz Is Third Player In HA Osteoarthritis Market
This article was originally published in The Gray Sheet
Executive Summary
Smith & Nephew's 400-rep sales force plans to emphasize the extensive clinical experience behind the firm's Supartz hyaluronic acid-based injectable treatment for osteoarthritis of the knee in marketing the product to orthopedic surgeons.
You may also be interested in...
Smith & Nephew Supartz Promotional Claims Draw Scrutiny From FDA, NAD
Smith & Nephew should take steps to ensure that device promotional brochures with claims not intended for U.S. markets are not circulated domestically, according to the National Advertising Division of the Council of Better Business Bureaus
Smith & Nephew Supartz Promotional Claims Draw Scrutiny From FDA, NAD
Smith & Nephew should take steps to ensure that device promotional brochures with claims not intended for U.S. markets are not circulated domestically, according to the National Advertising Division of the Council of Better Business Bureaus
OrthoLogic
Firm no longer co-markets Hyalgan osteoarthritis treatment, as was reported in "The Gray Sheet" (July 9, 2001, p. 9); the arrangement expired at the end of 2000 (1"The Gray Sheet" Feb. 5, 2001, p. 4)